A digital assay for programmed death-ligand 1 (22C3) quantification combined with immune cell recognition algorithms in non-small cell lung cancer

A digital assay for programmed death-ligand 1 (22C3) quantification combined with immune cell recognition algorithms in non-small cell lung cancer

Abstract PD-L1 (22C3) checkpoint inhibitor therapy represents a mainstay of modern cancer immunotherapy for non-small cell lung cancer (NSCLC). In vitro diagnostic (IVD) PD-L1 antibody staining is widely used to predict clinical intervention efficacy. However, pathologist interpretation of this assa...

Full description

Bibliographic Details
Main Authors: Will Paces, Elliott Ergon, Elizabeth Bueche, G. Dave Young, Vitria Adisetiyo, Cris Luengo, Meredith James, Charles Caldwell, Dannah Miller, Morgan Wambaugh, Geoffrey Metcalf, Roberto Gianani
Format: Article
Language:English
Published: Nature Portfolio 2022-06-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-022-12697-1

Internet

https://doi.org/10.1038/s41598-022-12697-1

Similar Items